These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26183205)

  • 21. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
    Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
    Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1.
    Wu W; Nelson GM; Koch R; Donovan KA; Nowak RP; Heavican-Foral TB; Nirmal AJ; Liu H; Yang L; Duffy J; Powers F; Stevenson KE; Jones MK; Ng SY; Wu G; Jain S; Xu R; Amaka S; Trevisani C; Donaldson NL; Hagner PR; de Leval L; Gaulard P; Iqbal J; Thakurta A; Fischer ES; Adelman K; Weinstock DM
    Blood; 2022 Mar; 139(13):2024-2037. PubMed ID: 34936696
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The interacting domains in cereblon differentially modulate the immunomodulatory drug-mediated ubiquitination and degradation of its binding partners.
    Tao J; Yang J; Xu G
    Biochem Biophys Res Commun; 2018 Dec; 507(1-4):443-449. PubMed ID: 30458989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aiolos collaborates with Blimp-1 to regulate the survival of multiple myeloma cells.
    Hung KH; Su ST; Chen CY; Hsu PH; Huang SY; Wu WJ; Chen MJ; Chen HY; Wu PC; Lin FR; Tsai MD; Lin KI
    Cell Death Differ; 2016 Jul; 23(7):1175-84. PubMed ID: 26823144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations.
    Lim SL; Damnernsawad A; Shyamsunder P; Chng WJ; Han BC; Xu L; Pan J; Pravin DP; Alkan S; Tyner JW; Koeffler HP
    Haematologica; 2019 Jun; 104(6):1209-1220. PubMed ID: 30606790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
    Gao S; Geng C; Song T; Lin X; Liu J; Cai Z; Cang Y
    J Biol Chem; 2017 Mar; 292(9):3683-3691. PubMed ID: 28087699
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Molecular Mechanism of CRBN in the Activity of Lenalidomid eagainst Myeloma--Review].
    Fan WJ; Fan ZQ; Yang MJ; Pan YZ; Bai H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Aug; 26(4):1240-1243. PubMed ID: 30111438
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of Pim2 kinase stability and expression in transformed human haematopoietic cells.
    Adam K; Lambert M; Lestang E; Champenois G; Dusanter-Fourt I; Tamburini J; Bouscary D; Lacombe C; Zermati Y; Mayeux P
    Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26500282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IMiD compounds affect CD34
    Li S; Fu J; Wang H; Ma H; Xu X; Yang YG; Deng S; Mapara MY; Lentzsch S
    Blood Adv; 2018 Mar; 2(5):492-504. PubMed ID: 29496670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Roscovitine, a small molecule CDK inhibitor induces apoptosis in multidrug-resistant human multiple myeloma cells.
    Komina O; Nosske E; Maurer M; Wesierska-Gadek J
    J Exp Ther Oncol; 2011; 9(1):27-35. PubMed ID: 21275263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
    Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
    Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ubiquitin-conjugating enzyme UBE2O modulates c-Maf stability and induces myeloma cell apoptosis.
    Xu Y; Zhang Z; Li J; Tong J; Cao B; Taylor P; Tang X; Wu D; Moran MF; Zeng Y; Mao X
    J Hematol Oncol; 2017 Jul; 10(1):132. PubMed ID: 28673317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma.
    Liu M; Zhang Y; Wu Y; Jin J; Cao Y; Fang Z; Geng L; Yang L; Yu M; Bu Z; Ji Y; Shan H; Zou Z; Liu L; Wang Y; Zhang Y; Tong Y; Xu H; Lei H; Liu W; Gao F; Wu Y
    Int J Biol Sci; 2022; 18(6):2515-2526. PubMed ID: 35414773
    [No Abstract]   [Full Text] [Related]  

  • 34. Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.
    Lin Z; Zhang Y; Liu X; Luo H; Li Q; Gao Q; Wang X; Wen J; Li L; Feng Y; Wang F; Huang J; Zhai X; Zhang L; Niu T; Zheng Y
    Br J Haematol; 2024 Aug; 205(2):594-606. PubMed ID: 38685577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. p97/VCP promotes degradation of CRBN substrate glutamine synthetase and neosubstrates.
    Nguyen TV; Li J; Lu CJ; Mamrosh JL; Lu G; Cathers BE; Deshaies RJ
    Proc Natl Acad Sci U S A; 2017 Apr; 114(14):3565-3571. PubMed ID: 28320958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.
    Awwad MHS; Kriegsmann K; Plaumann J; Benn M; Hillengass J; Raab MS; Bertsch U; Munder M; Weisel K; Salwender HJ; Hänel M; Fenk R; Dürig J; Müller-Tidow C; Goldschmidt H; Hundemer M
    Oncoimmunology; 2018; 7(10):e1486356. PubMed ID: 30288348
    [No Abstract]   [Full Text] [Related]  

  • 37. The evolving tale of immunomodulatory drugs and cereblon.
    Holstein SA
    Clin Pharmacol Ther; 2014 Nov; 96(5):538-41. PubMed ID: 25144833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New mechanism of lenalidomide activity.
    Keevan J; Figg WD
    Cancer Biol Ther; 2014 Aug; 15(8):968-9. PubMed ID: 24840055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lenalidomide induces degradation of IKZF1 and IKZF3.
    Krönke J; Hurst SN; Ebert BL
    Oncoimmunology; 2014; 3(7):e941742. PubMed ID: 25610725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos.
    Fedele PL; Willis SN; Liao Y; Low MS; Rautela J; Segal DH; Gong JN; Huntington ND; Shi W; Huang DCS; Grigoriadis G; Tellier J; Nutt SL
    Blood; 2018 Nov; 132(20):2166-2178. PubMed ID: 30228232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.